SOURCE-LINKED STUDY SUMMARY
NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis.
Full paper summarizedQuality not appraised
- What was studied
- A randomized placebo-controlled pilot and laboratory experiments investigated NR effects on inflammatory signaling in psoriasis.
- Who / model studied
- 27 volunteers with mild-to-moderate psoriasis were recruited; additional experiments used human immune cells and skin fibroblasts.
- Studied dose & schedule
- Oral NR 500 mg twice daily or matching placebo for 4 weeks.
- What the study found
- NR reduced Th17 immune responsiveness and increased circulating SLIT2. Cell experiments implicated SLIT2/ROBO1 signaling in dampening inflammatory activation. No serious adverse effects were reported.
- Limitations & context
- Small, short mechanistic study, not an efficacy-powered psoriasis treatment trial. Immune-cell changes do not establish skin clearance, durable symptom improvement or benefits in healthy people.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1172/jci.insight.203826